A carregar...
Oral administration of a new HRI activator as a new strategy to improve high‐fat‐diet‐induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21
BACKGROUND AND PURPOSE: FGF21 has emerged as a therapeutic strategy for treating type 2 diabetes mellitus due to its antidiabetic effects, and this has led to the development of long‐acting analogues of FGF21. However, these compounds have some limitations, including a need to be administered by s.c...
Na minha lista:
| Publicado no: | Br J Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6555855/ https://ncbi.nlm.nih.gov/pubmed/30927369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14678 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|